Requip PD Adverse Reactions

Adverse events are listed as follows by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1,000), very rare (<1/10,000), including isolated reports.
During clinical trials, the most commonly reported adverse events for REQUIP PD prolonged release tablets were during monotherapy and dyskinesia during adjunctive therapy with levedopa.
The following adverse events were reported during clinical trials with REQUIP PD up to 24 mg / day. (See Table 3.)

Click on icon to see table/diagram/image

In addition to the previously mentioned adverse events, the following events have been reported with REQUIP (immediate-release) tablets in patient during clinical trials (at doses up to 24 mg / day) and / or post-marketing reports. (See Table 4.)

Click on icon to see table/diagram/image

Dopamine agonist withdrawal syndrome: Non-motor adverse effects may occur when tapering or discontinuing dopamine agonists including ropinirole (see Precautions).
Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including REQUIP PD (see Precautions).